Europe Multiple Myeloma Therapeutics Market Competitive landscape analysis
The Europe Multiple Myeloma Therapeutics Market was worth $1.8 billion in 2016 and estimated to be growing at a CAGR of 4.58%, to reach $2.25 billion by 2021.
(EMAILWIRE.COM, September 08, 2017 ) Europe is the second largest market among regions after North America.The Multiple Myeloma (MM) market is presently dominated by Velcade and Revlimid, and the market is set to experience considerable growth between 2016 and 2021. As multiple myeloma market is mostly irredeemable and is regularly characterised by a cycle of reduction and relapse, there is an acute need for new treatments for patients that work in distinctive and innovative ways.
View Full Report @ http://www.marketdataforecast.com/market-reports/europe-multiple-myeloma-therapeutics-market-860/
Improved investments in R&D in the pharmaceutical area, absence of healing drugs for blood diseases and the introduction of advanced drugs have fuelled the growth of multiple myeloma therapeutics market. Therapies such as radiation therapy, chemotherapy, physiotherapy, and biological therapy have huge potential to outgrowth the market. The patent terminations of some bestselling drugs have obstructed the growth of the market.
Free sample of the report is available @ http://www.marketdataforecast.com/market-reports/europe-multiple-myeloma-therapeutics-market-860/request-sample
The Europe Multiple Myeloma Therapeutics Market is segmented on the basis of Treatment Type into Chemotherapy which is further segmented into Anthracycline Antibiotic (Melphalan (Alkeran), Liposomal doxorubicin (Doxil)) and Alkylating agent (Doxorubicin (Adriamycin), Cyclophosphamide (Neosar), Vincristine (Oncovin), Carmustine (BiCNU)) and Targeted Therapy ( Proteasome Inhibitor (Bortezomib (Velcade), Carfilzomib (Kyprolis)), by Drug Type into Corticosteroids (Dexamethasone (Decadron), Prednisone (Deltasone/Orasone)) and Immunomodulatory Agents (Thalidomide (Thalomid), Lenalidomide (Revlimid), Arsenic trioxide (Trisenox), Plerixafor (Mozobil)). With the advancement in technology targeted therapy is on a high growth due to its advantages over chemotherapy such as lesser side effects.
Inquire before buying @ http://www.marketdataforecast.com/market-reports/europe-multiple-myeloma-therapeutics-market-860/inquire
Based on geography the market is analysed under various regions namely, Germany, Italy, France, Spain and U.K. France is the largest market for multiple myeloma therapeutics in the European region while Italy and Spain are estimated to grow at highest CAGR.
Some of the key contributors in the industry include AB Science SA, AbbVie Inc., Ablynx NV, Acceleron Pharma Inc., IGF Oncology LLC. , ImmunGene Inc., Millennium Pharmaceuticals Inc., MimiVax LLC, Mirna Therapeutics, RedHill Biopharma Ltd., Rhizen Pharmaceuticals S.A., Terpenoid Therapeutics Inc. ,Teva Pharmaceutical Industries Ltd. ,TG Therapeutics Inc. and Johnson and Johnson.
About Us:
Market Data Forecast is a firm working in the area of market research and business intelligence. With rich experience in research across various business domains, we cater to the needs of both individual and corporate clients. Our analyst team comprises expert professionals in market research, who with their collective knowledge and sksillset dedicatedly serve clients from various industries and regions.
Contact:
Abhishek Shukla
Sales Manager (International Business Development)
Market Data Forecast
Direct Line: +1-888-702-9626
Mobile: +91 998 555 0206
Mail: abhishek@marketdataforecast.com
Visit MarketDataForecast Blog @ http://www.marketdataforecast.com/blog/
View latest Press Releases of MDF @ http://www.marketdataforecast.com/press-releases
View Full Report @ http://www.marketdataforecast.com/market-reports/europe-multiple-myeloma-therapeutics-market-860/
Improved investments in R&D in the pharmaceutical area, absence of healing drugs for blood diseases and the introduction of advanced drugs have fuelled the growth of multiple myeloma therapeutics market. Therapies such as radiation therapy, chemotherapy, physiotherapy, and biological therapy have huge potential to outgrowth the market. The patent terminations of some bestselling drugs have obstructed the growth of the market.
Free sample of the report is available @ http://www.marketdataforecast.com/market-reports/europe-multiple-myeloma-therapeutics-market-860/request-sample
The Europe Multiple Myeloma Therapeutics Market is segmented on the basis of Treatment Type into Chemotherapy which is further segmented into Anthracycline Antibiotic (Melphalan (Alkeran), Liposomal doxorubicin (Doxil)) and Alkylating agent (Doxorubicin (Adriamycin), Cyclophosphamide (Neosar), Vincristine (Oncovin), Carmustine (BiCNU)) and Targeted Therapy ( Proteasome Inhibitor (Bortezomib (Velcade), Carfilzomib (Kyprolis)), by Drug Type into Corticosteroids (Dexamethasone (Decadron), Prednisone (Deltasone/Orasone)) and Immunomodulatory Agents (Thalidomide (Thalomid), Lenalidomide (Revlimid), Arsenic trioxide (Trisenox), Plerixafor (Mozobil)). With the advancement in technology targeted therapy is on a high growth due to its advantages over chemotherapy such as lesser side effects.
Inquire before buying @ http://www.marketdataforecast.com/market-reports/europe-multiple-myeloma-therapeutics-market-860/inquire
Based on geography the market is analysed under various regions namely, Germany, Italy, France, Spain and U.K. France is the largest market for multiple myeloma therapeutics in the European region while Italy and Spain are estimated to grow at highest CAGR.
Some of the key contributors in the industry include AB Science SA, AbbVie Inc., Ablynx NV, Acceleron Pharma Inc., IGF Oncology LLC. , ImmunGene Inc., Millennium Pharmaceuticals Inc., MimiVax LLC, Mirna Therapeutics, RedHill Biopharma Ltd., Rhizen Pharmaceuticals S.A., Terpenoid Therapeutics Inc. ,Teva Pharmaceutical Industries Ltd. ,TG Therapeutics Inc. and Johnson and Johnson.
About Us:
Market Data Forecast is a firm working in the area of market research and business intelligence. With rich experience in research across various business domains, we cater to the needs of both individual and corporate clients. Our analyst team comprises expert professionals in market research, who with their collective knowledge and sksillset dedicatedly serve clients from various industries and regions.
Contact:
Abhishek Shukla
Sales Manager (International Business Development)
Market Data Forecast
Direct Line: +1-888-702-9626
Mobile: +91 998 555 0206
Mail: abhishek@marketdataforecast.com
Visit MarketDataForecast Blog @ http://www.marketdataforecast.com/blog/
View latest Press Releases of MDF @ http://www.marketdataforecast.com/press-releases
Contact Information:
Market Data Forecast.
Abhishek
Tel: +1-888- 702-9626
Email us
----
This press release is posted on EmailWire.com -- a global newswire that provides Press Release Distribution Services with Guaranteed Results
Market Data Forecast.
Abhishek
Tel: +1-888- 702-9626
Email us
----
This press release is posted on EmailWire.com -- a global newswire that provides Press Release Distribution Services with Guaranteed Results